Trimetazidin effektiven v reabilitatsii bol'nykh posle protezirovaniya klapanov serdtsa: rezul'taty randomizirovannogo kontroliruemogo godichnogo issledovaniya
- Authors: Gaysin I.R1, Gazimzyanova A.S1, Sokolova T.V1, Maksimov N.I1, Galimova A.A1, Voronova M.A1, Chernykh E.A1, Poyarkina I.R1
-
Affiliations:
- Issue: No 6 (2014)
- Pages: 6-11
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/286831
- ID: 286831
Cite item
Abstract
Full Text
About the authors
I. R Gaysin
Email: igaisin@mail.ru
A. S Gazimzyanova
T. V Sokolova
N. I Maksimov
A. A Galimova
M. A Voronova
E. A Chernykh
I. R Poyarkina
References
- Iung B., Baron G., Butchart E.G., et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur. Heart J. 2003;24:1231-43.
- Nkomo V.T., Gardin J.M., Skelton T.N., et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368:1005-11.
- Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect. Dis. 2005;5: 685-94.
- Coffey S., Cox B., Williams M.J.A. The increasing mortality of valvular heart disease. Eur. Heart. J. 2012;32(Suppl.):526.
- Vahanian A., et al. Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart. J. doi: 10.1093/eurheartj/ehs10.
- Rozen G., et al. Surgical aortic valve replacement for severe aortic stenosis in the era of transcatheter implantation. Eur. Heart. J. 2012;32 (Suppl.):212.
- Бураковский В.И., Бокерия Л.А. Сердечно-сосудистая хирургия: руководство. М., 1989. 742 с.
- Лещинский Л.А., Одиянков Е.Г., Валеева Р.М. 10 лет большой кардиохирургии в Удмуртской Республике: учебно-методический сборник. Ижевск, 2003. 336 с.
- Zhang L., Lu Y., Jiang H., et al. Дополнительная терапия триметазидином у больных хронической сердечной недостаточностью. Мета-анализ. Рацион. фармакотерапия в кардиологии. 2012;2:242-50.
- Kantor P.F., Lucien A., Kozak R., Lopaschuk G.D. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 2000;86:580-88.
- Katz A.M. Is the failing heart energy depleted? Cardiol. Clin. 1998;16:633-44.
- Williams F.M., Tanda K., Kus M., Williams T.J. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfu sion in rabbits. J. Cardiovasc. Pharmacol. 1993;22:828-33.
- Di Napoli P., Chierchia S., Taccardi A.A., et al. Trimetazidine improves post-ischemic recovery by preserving endothelial nitric oxide synthase expression in isolated working rat hearts. Nitric. Oxide-Biol. Ch. 2007;16:228-36.
- Ruixing Y., Wenwu L., Al-Ghazali R. Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion. Transl. Res. 2007;149:152-60.
- Belardinelli R., Solenghi M., Volpe L., Purcaro A. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur. Heart J. 2007;28:1102-108.
- Lee L., Horowitz J., Frenneaux M. Metabolic manipulation in ischemic heart disease, a novel approach to treatment. Eur. Heart. J. 2004;25:634-41.
- Levin E.R., Gardner D.G., Samson W.K. Mechanisms of disease - natriuretic peptides. New Engl. J. Med. 1998;339:321-28.
- World Health Organization. Basic Documents. 26th ed. Geneva, 1976.